Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)
Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is a medication used for weight loss, type 2 diabetes management, and cardiovascular risk reduction.
The sponsor of a clinical trial, which may be a pharmaceutical company or an academic institution, is responsible for submitting information about their study to the ClinicalTrials.gov database.
Laboratory tests are often part of the safety assessment in clinical trials of unlisted drugs, and blood samples are used for clinical biochemistry and blood.
The trial protocol should strictly define what subjects can be enrolled (enrollment criteria) and what subjects cannot be enrolled (exclusion criteria).